X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (117) 117
male (73) 73
index medicus (66) 66
oncology (65) 65
female (64) 64
middle aged (48) 48
animals (46) 46
aged (38) 38
adult (37) 37
cell biology (36) 36
cancer (33) 33
chemotherapy (29) 29
hematology (29) 29
prognosis (28) 28
rats (26) 26
treatment outcome (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
pathology (20) 20
rituximab (19) 19
aged, 80 and over (18) 18
cell division (18) 18
retrospective studies (18) 18
disease-free survival (16) 16
microscopy, electron (16) 16
non-hodgkins-lymphoma (16) 16
p53 (16) 16
cell line, tumor (15) 15
gastroenterology & hepatology (15) 15
mice (15) 15
chromatin - ultrastructure (14) 14
lymphomas (14) 14
tumor cells, cultured (14) 14
hemic and lymphatic diseases (13) 13
liver - ultrastructure (13) 13
cell proliferation (12) 12
follicular lymphoma (12) 12
liver - metabolism (12) 12
staining and labeling (12) 12
b-cell lymphoma (11) 11
cell cycle (11) 11
lymphoma (11) 11
nucleolar organizer regions (11) 11
nucleolus (11) 11
radioimmunotherapy (11) 11
research (11) 11
risk factors (11) 11
time factors (11) 11
tumor suppressor protein p53 - metabolism (11) 11
young adult (11) 11
care and treatment (10) 10
cyclophosphamide - administration & dosage (10) 10
expression (10) 10
follow-up studies (10) 10
silver-stained proteins (10) 10
vincristine - administration & dosage (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
cell nucleolus - ultrastructure (9) 9
cells (9) 9
genetic aspects (9) 9
lymphoma, large b-cell, diffuse - drug therapy (9) 9
remission induction (9) 9
retinoblastoma protein (9) 9
ribosomes - metabolism (9) 9
rna, ribosomal - biosynthesis (9) 9
silver staining (9) 9
survival (9) 9
activation (8) 8
apoptosis (8) 8
breast neoplasms - metabolism (8) 8
carcinoma, hepatocellular - pathology (8) 8
doxorubicin - administration & dosage (8) 8
hematology, oncology and palliative medicine (8) 8
immune system diseases (8) 8
immunohistochemistry (8) 8
liver - cytology (8) 8
liver - pathology (8) 8
liver neoplasms - pathology (8) 8
liver regeneration (8) 8
neoplasms - pathology (8) 8
nucleolus organizer region - ultrastructure (8) 8
prednisone - administration & dosage (8) 8
prospective studies (8) 8
recurrence (8) 8
review (8) 8
rna, ribosomal - genetics (8) 8
survival analysis (8) 8
trial (8) 8
ag-nor proteins (7) 7
agnor proteins (7) 7
analysis (7) 7
antibodies, monoclonal - adverse effects (7) 7
antibodies, monoclonal, murine-derived - administration & dosage (7) 7
biomarkers, tumor - metabolism (7) 7
biosynthesis (7) 7
blotting, western (7) 7
breast cancer (7) 7
breast neoplasms - pathology (7) 7
c-myc (7) 7
cell-proliferation (7) 7
combined modality therapy (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncogene, ISSN 0950-9232, 08/2014, Volume 33, Issue 35, pp. 4396 - 4406
Chronic inflammation is an established risk factor for the onset of cancer, and the inflammatory cytokine IL-6 has a role in tumorigenesis by enhancing... 
LIVER INFLAMMATION | IMMUNITY | ACTIVATION | RNA | BIOCHEMISTRY & MOLECULAR BIOLOGY | STAT3 | E-CADHERIN | EMT | MULTIPLE-MYELOMA CELLS | IL-6 | C-MYC TRANSLATION | p53 | CELL BIOLOGY | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | GENETICS & HEREDITY | cancer | chronic inflammation | ribosome biogenesis | Cadherins - metabolism | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Ribosomes - metabolism | Epithelial-Mesenchymal Transition - drug effects | Male | RNA, Ribosomal - genetics | Colonic Neoplasms - metabolism | Tumor Suppressor Protein p53 - genetics | Ribosomal Proteins - metabolism | Anti-Inflammatory Agents - therapeutic use | Adult | Female | Colitis, Ulcerative - drug therapy | Proto-Oncogene Proteins c-mdm2 - metabolism | Signal Transduction | Colitis, Ulcerative - metabolism | Tumor Suppressor Protein p53 - metabolism | RNA, Ribosomal - metabolism | Colitis, Ulcerative - pathology | Proto-Oncogene Proteins c-myc - metabolism | Hep G2 Cells | Gene Expression Regulation - drug effects | Interleukin-6 - pharmacology | Ribosomes - genetics | Colonic Neoplasms - pathology | Cell Line, Tumor | Proto-Oncogene Proteins c-myc - genetics | Development and progression | Inflammation | Genetic aspects | Tumor proteins | Properties | Carcinogenesis | Interleukin-6 | Oncology | Biosynthesis | Ribonucleic acid--RNA | Inflammatory diseases | Cancer | Original
Journal Article
Journal Article
Cell Reports, ISSN 2211-1247, 08/2018, Volume 24, Issue 8, pp. 2155 - 2166
The phosphatidylinositol 3 kinase (PI3K)-glycogen synthase kinase β (GSK3β) axis plays a central role in MYC-driven lymphomagenesis, and MYC targeting with... 
GSK3β | DLBCL | PI3K | diffuse large B cell lymphoma | MYC | lymphoma | BET inhibitor | JQ1 | B-CELL LYMPHOMA | ANAPHASE-PROMOTING COMPLEX | ACTIVATION | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | PATHWAY | C-MYC | AKT | KAPPA-B | CANCER | CELL BIOLOGY
Journal Article
Blood Cancer Journal, ISSN 2044-5385, 12/2011, Volume 1, Issue 12, pp. e46 - e46
Aberrant activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been reported to promote proliferation and... 
AZD1480 | Aurora kinases | JAK2 | ERK | Hodgkin lymphoma | SURVIVAL | REED-STERNBERG CELLS | KINASE | CYCLE ARREST | CYTOKINE | LINES | IN-VITRO | ONCOLOGY | EMBRYONIC STEM-CELLS | GROWTH | AURORA | Original
Journal Article
Journal Article
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 4/2008, Volume 19, Issue 4, pp. 769 - 773
Background: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and... 
Chemotherapy | DLBCL | Yttrium 90 ibritumomab tiuxetan | Elderly patients | elderly patients | TOSITUMOMAB/IODINE I-131 TOSITUMOMAB | EFFICACY | SAFETY | R-CHOP | RADIOIMMUNOTHERAPY | MODEL | chemotherapy | yttrium 90 ibritumomab tiuxetan | THERAPY | GROUP PROTOCOL S9911 | ONCOLOGY | RITUXIMAB | NON-HODGKINS-LYMPHOMA | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Cyclophosphamide - adverse effects | Feasibility Studies | Neutropenia - etiology | Aged, 80 and over | Radioimmunotherapy - methods | Vincristine - administration & dosage | Female | Yttrium Radioisotopes - therapeutic use | Doxorubicin - administration & dosage | Yttrium Radioisotopes - adverse effects | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Thrombocytopenia - etiology | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - radiotherapy | Remission Induction | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus
Journal Article